Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Inc. is trading at $36.44, up 0.77% on the session. The 50 day average sits at $55.87 and the 200 day at $53.07, which puts the stock in a uptrend. RSI is at 23.7, which reads as oversold, and MACD is bearish crossover. Volume is below average.

The nearest support is around $36.07 with resistance near $61.75, so that band frames the current range. Average daily movement is roughly $2.31, or about 6.3% of the share price, which is what any stop placement has to allow for. The overall health score of 31 out of 100 combines a trend score of 30, momentum of 28 and a risk score of 36.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.